Processa Pharmaceuticals, Inc. (PCSA) compared with its closest peers (CNSP, XBIO, APUS, BOLT, ACXP). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $8.57M | -0.1 |
| Xenetic Biosciences, Inc. (XBIO) | $8.22M | -1.4 |
| Apimeds Pharmaceuticals US, Inc (APUS) | $7.74M | -2.9 |
| Bolt Biotherapeutics, Inc. (BOLT) | $7.19M | -0.3 |
| Acurx Pharmaceuticals, Inc. (ACXP) | $6.36M | -0.5 |
| Enveric Biosciences, Inc. (ENVB) | $6.36M | -0.1 |
| Dermata Therapeutics, Inc. (DRMA) | $5.67M | -0.3 |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $5.60M | -1.0 |
| PMGC Holdings Inc. (ELAB) | $5.34M | -0.0 |
| AEON Biopharma, Inc. (AEON) | $5.12M | -0.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
PCSA overview · PCSA earnings · PCSA financials · PCSA KPIs · PCSA investor relations · PCSA ownership · PCSA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.